Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

被引：0
|
作者：
Gabe S. Sonke
Lowell L. Hart
Mario Campone
Frans Erdkamp
Wolfgang Janni
Sunil Verma
Cristian Villanueva
Erik Jakobsen
Emilio Alba
Erik Wist
Anne M. Favret
Thomas Bachelot
Roberto Hegg
Paul Wheatley-Price
Farida Souami
Santosh Sutradhar
Michelle Miller
Caroline Germa
Howard A. Burris
机构：
[1] Netherlands Cancer Institute/BOOG Study Center,Department of Medical Oncology
[2] Florida Cancer Specialists,Zuyderland Medical Center
[3] Sarah Cannon Research Institute,University Hospital of Besançon
[4] Institut de Cancérologie de l’Ouest – René Gauducheau Centre de Recherche en Cancérologie,Virginia Cancer Specialists PC
[5] Sittard-Geleen/Heerlen,Ottawa Hospital Research Institute
[6] Universitätsklinikum Ulm,undefined
[7] Tom Baker Cancer Centre,undefined
[8] Hospital Jean-Minjoz,undefined
[9] Lillebælt Hospital,undefined
[10] Hospital Universitario Virgen de la Victoria,undefined
[11] IBIMA,undefined
[12] Oslo University Hospital,undefined
[13] US Oncology,undefined
[14] Centre Léon Bérard,undefined
[15] Hospital Pérola Byington Centro de Referência da Saúde da Mulher,undefined
[16] University of Ottawa,undefined
[17] Novartis Pharma AG,undefined
[18] Novartis Pharmaceuticals Corporation,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Breast cancer; CDK inhibitor; Ribociclib; Endocrine therapy; Elderly; Hormone receptor-positive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：659 / 669
页数：10
相关论文
共 50 条
  • [1] Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
    Sonke, Gabe S.
    Hart, Lowell L.
    Campone, Mario
    Erdkamp, Frans
    Janni, Wolfgang
    Verma, Sunil
    Villanueva, Cristian
    Jakobsen, Erik
    Alba, Emilio
    Wist, Erik
    Favret, Anne M.
    Bachelot, Thomas
    Hegg, Roberto
    Wheatley-Price, Paul
    Souami, Farida
    Sutradhar, Santosh
    Miller, Michelle
    Germa, Caroline
    Burris, Howard A.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 659 - 669
  • [2] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [3] Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib plus letrozole vs placebo plus letrozole in the phase III MONALEESA-2 study
    Blackwell, Kimberly L.
    Paluch-Shimon, Shani
    Campone, Mario
    Conte, Pierfranco
    Petrakova, Katarina
    Favret, Anne
    Blau, Sibel
    Beck, J. Thaddeus
    Miller, Michelle
    Sutradhar, Santosh
    Monaco, Mauricio
    Burris, Howard A.
    CANCER RESEARCH, 2018, 78 (04)
  • [4] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, C. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
  • [5] Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
    Joyce O’Shaughnessy
    Katarina Petrakova
    Gabe S. Sonke
    Pierfranco Conte
    Carlos L. Arteaga
    David A. Cameron
    Lowell L. Hart
    Cristian Villanueva
    Erik Jakobsen
    Joseph T. Beck
    Deborah Lindquist
    Farida Souami
    Shoubhik Mondal
    Caroline Germa
    Gabriel N. Hortobagyi
    Breast Cancer Research and Treatment, 2018, 168 : 127 - 134
  • [6] Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial
    O'Shaughnessy, Joyce
    Petrakova, Katarina
    Sonke, Gabe S.
    Conte, Pierfranco
    Arteaga, Carlos L.
    Cameron, David A.
    Hart, Lowell L.
    Villanueva, Cristian
    Jakobsen, Erik
    Beck, Joseph T.
    Lindquist, Deborah
    Souami, Farida
    Mondal, Shoubhik
    Germa, Caroline
    Hortobagyi, Gabriel N.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 127 - 134
  • [7] First-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2
    Hortobagyi, Gabriel N.
    Stemmer, Salomon
    Campone, Mario
    Sonke, Gabe S.
    Arteaga, Carlos L.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Nusch, Arnd
    Grischke, Eva-Maria
    Chan, Arlene
    Jakobsen, Erik
    Marschner, Norbert
    Hart, Lowell L.
    Alba, Emilio
    Ohnstand, Hege O.
    Blau, Sibel
    Yardley, Denise A.
    Solovieff, Nadia
    Su, Faye
    Germa, Caroline
    Yap, Yoon-Sim
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [9] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
    Hortobagyi, Gabriel N.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Chan, Arlene
    Nusch, Arnd
    Yap, Yoon Sim
    Hart, Lowell
    Favret, Anne
    Marschner, Norbert
    Sonke, Gabe S.
    Ohnstad, Hege Oma
    Arteaga, Carlos
    Su, Fei
    He, Wei
    Miller, Michelle Kristine
    Stemmer, Salomon M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345